SWOG is a research organization with cancer investigators distributed across 550 academic and community sites throughout the U.S. Canada, Latin America, Korea, and Saudi Arabia. The Group has a long history of conducting clinical trials that have changed standard of oncologic practice and that have led to Food and Drug Administration approval of new anti-neoplastic agents. SWOG's mission is to design, direct and participate in clinical trials that will result in effective prevention and treatment of cancer in the process improving quality of life and quality of survivorship for those with malignancies. Guiding principles used to help achieve these goals include placing patients as our highest priority, using the best science to drive our research, embracing diversity in membership and leadership, demanding ethical behavior, and fostering young investigators. SWOG's specific aims for this application include Improving efficiency and rapidly executing the clinical trial development and conduct processes;collaborating widely to reduce accrual barriers and facilitate participation in NCTN trials;maximizing potential from international partners by studying globally-significant cancers;and being active participants and leaders in NCTN management. Building on our successful past while significantly moving forward, SWOG will be a clinical trials organization dedicated to conducting high-value, high-impact cancer trials.

Agency
National Institute of Health (NIH)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180888-01
Application #
8605343
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Portland
State
OR
Country
United States
Zip Code
97239
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2016) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv :
Halabi, Susan; Kelly, William Kevin; Ma, Hua et al. (2016) Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol 34:1652-9
Dickler, Maura N; Barry, William T; Cirrincione, Constance T et al. (2016) Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol 34:2602-9
Till, Brian G; Li, Hongli; Bernstein, Steven H et al. (2016) Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol 172:208-18
Hussain, Maha; Tangen, Catherine; Higano, Celestia et al. (2016) Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details. J Clin Oncol 34:280-5
Zent, Clive S; Victoria Wang, Xin; Ketterling, Rhett P et al. (2016) A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). Am J Hematol 91:308-12
Laport, Ginna G; Wu, Juan; Logan, Brent et al. (2016) Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Networ Biol Blood Marrow Transplant 22:1440-8
Margolese, Richard G; Cecchini, Reena S; Julian, Thomas B et al. (2016) Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387:849-56
Press, Oliver W; Li, Hongli; Schöder, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7
Prebet, Thomas; Sun, Zhuoxin; Ketterling, Rhett P et al. (2016) Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. Br J Haematol 172:384-91

Showing the most recent 10 out of 166 publications